Combination therapy for biochemically recurrent prostate cancer tested in new trial

Lipogenesis in Prostate Cancer

Lipogenesis in Prostate Cancer

Men with rising PSA after initial treatment for prostate cancer may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Prostate-specific antigen (PSA) is an enzyme released by the prostate gland and is found in abnormally high concentrations in the blood of men with prostate cancer. “Biochemical recurrence” is when PSA levels continue to rise after initial treatment for prostate cancer, such as surgery or radiation. Marijo Bilusic, M.D., of the Genitourinary Malignancies Branch is leading the Center for Cancer Research’s effort in a study to treat men with biochemically recurrent prostate cancer with a combination of metformin and bicalutamide. Metformin is usually given to people with diabetes to reduce the amount of sugar in their blood. However, many studies suggest that metformin may also slow the growth of prostate cancer tumors. Bicalutamide blocks the effects of male hormones that can stimulate the growth of prostate cancer cells. Investigators want to see if the drugs work better together than alone to slow the growth of prostate cancer tumors.

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.  

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Tue, 05/01/2018